Academic journal article Bulletin of the World Health Organization

Ebola Vaccine Trials Start

Academic journal article Bulletin of the World Health Organization

Ebola Vaccine Trials Start

Article excerpt

The first clinical trials of an experimental vaccine for Ebola virus disease in Africa started last month in Mali to test its safety and ability to provoke an immune response, or immunogenicity.

News of this and other vaccine trials came as the international community ramped up efforts to stop the outbreak that is ravaging parts of western Africa.

Clinical trials to test the safety and immunogenicity of the two leading Ebola vaccine candidates (ChimpAd3-EBO and rVSV-ZEBO) were also due to start in Switzerland last month. Both were to recruit about 120 volunteers with the aim of determining the vaccine dose level needed in subsequent trials to test the vaccines' efficacy in western Africa.

Usually clinical trials take years to complete, but if all goes well, one or more of these vaccines could be ready in several months' time to protect frontline workers and the community in the current outbreak in western Africa.

The two vaccine candidates were reviewed by more than 70 international experts, gathered at WHO headquarters in Geneva on 29 and 30 September. The ChimpAd3-EBO vaccine is being developed by GlaxoSmithKline in collaboration with the US National Institute of Allergy and Infectious Diseases and is also being tested in the United Kingdom and the United States of America. The rVSV-ZEBO vaccine is being developed by US pharmaceutical company NewLink Genetics and the Public Health Agency of Canada. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.